RxDoctor Payments Data

Martin Krakower, MD

Family Medicine · Woodstock, NYNPI 1073615738

Payments from drug & device makers

$1,872in general payments, 2019–2025

Across 82 payments — averaging $22.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$508
  • Lilly USA, LLC$316
  • UCB, Inc.$183
  • Teva Pharmaceuticals USA, Inc.$155
  • Boehringer Ingelheim$152
  • AstraZeneca$87
  • plus $471 from 12 others

What the payments were for

  • Food & beverage$1,872100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,872 in reported general payments places this provider in the 75th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$52,947
Medicare patients
166
Services billed
620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate43$53,903
EliquisApixaban32$25,531
OzempicSemaglutide22$21,771
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$18,943
TradjentaLinagliptin11$15,679
Combivent RespimatIpratropium/Albuterol Sulfate17$8,397
XareltoRivaroxaban13$8,345
MyrbetriqMirabegron12$5,717
Hydrocodone-IbuprofenHydrocodone/Ibuprofen19$4,455
Breo ElliptaFluticasone/Vilanterol11$3,969
Oxycodone Hcl102$3,828
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,243
Albuterol Sulfate HfaAlbuterol Sulfate71$2,402
Morphine Sulfate ErMorphine Sulfate34$2,112
Atorvastatin Calcium212$1,701

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$53$25,53132 claims
Boehringer IngelheimTradjenta, Combivent Respimat$152$24,07628 claims
GSKTrelegy Ellipta, Breo Ellipta$78$22,91131 claims
Novo NordiskOzempic$33$21,77122 claims
AbbVieSynthroid$508$70614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,321 family medicine providers in New York.

Other family medicine in Woodstock

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →